Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DARENASDAQ:GBIONASDAQ:GDTCNASDAQ:PRPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAREDare Bioscience$2.40$2.87$2.35▼$4.60$21.24M1.1435,448 shs118,793 shsGBIOGeneration Bio$0.33-3.8%$0.38$0.30▼$3.65$22.99M2.59395,522 shs507,866 shsGDTCCytoMed Therapeutics$2.15-2.3%$2.23$1.20▼$4.05N/A-0.3678,049 shs9,249 shsPRPHProPhase Labs$0.44+5.6%$0.35$0.22▼$3.74$17.39M-0.413.14 million shs915,783 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAREDare Bioscience0.00%+0.42%-25.00%-17.24%-23.81%GBIOGeneration Bio-5.17%+3.09%-24.31%+1.85%-84.72%GDTCCytoMed Therapeutics+2.38%-4.44%+4.88%-4.02%+2.87%PRPHProPhase Labs+8.89%+12.98%+23.49%+76.84%-86.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDAREDare Bioscience1.5479 of 5 stars3.35.00.00.00.00.00.0GBIOGeneration Bio2.9214 of 5 stars3.53.00.00.00.03.31.3GDTCCytoMed Therapeutics2.3143 of 5 stars3.55.00.00.01.80.00.0PRPHProPhase Labs0.7662 of 5 stars0.05.00.00.01.40.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAREDare Bioscience 2.50Moderate Buy$12.00400.00% UpsideGBIOGeneration Bio 3.00Buy$7.332,122.22% UpsideGDTCCytoMed Therapeutics 3.00Buy$5.00132.56% UpsidePRPHProPhase Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRPH, GDTC, DARE, and GBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/10/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAREDare Bioscience$10K2,124.00N/AN/A($0.69) per share-3.48GBIOGeneration Bio$19.89M1.11N/AN/A$1.29 per share0.26GDTCCytoMed Therapeutics$50KN/AN/AN/A$0.61 per shareN/APRPHProPhase Labs$6.77M2.71N/AN/A$0.25 per share1.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAREDare Bioscience-$4.05M-$0.17N/AN/AN/AN/AN/A-8.14%8/11/2025 (Estimated)GBIOGeneration Bio-$131.67M-$1.08N/AN/AN/A-292.92%-75.84%-30.40%8/6/2025 (Estimated)GDTCCytoMed Therapeutics-$1.84MN/A0.00∞N/AN/AN/AN/A7/28/2025 (Estimated)PRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-184.38%-64.59%8/13/2025 (Estimated)Latest PRPH, GDTC, DARE, and GBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025PRPHProPhase Labs-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million5/13/2025Q1 2025DAREDare Bioscience-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million5/7/2025Q1 2025GBIOGeneration Bio-$0.25-$0.22+$0.03-$0.22$1.70 million$8.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAREDare BioscienceN/AN/AN/AN/AN/AGBIOGeneration BioN/AN/AN/AN/AN/AGDTCCytoMed TherapeuticsN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAREDare BioscienceN/A0.560.56GBIOGeneration BioN/A8.438.43GDTCCytoMed Therapeutics0.059.899.89PRPHProPhase Labs0.301.030.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAREDare Bioscience6.70%GBIOGeneration Bio95.22%GDTCCytoMed Therapeutics0.04%PRPHProPhase Labs9.45%Insider OwnershipCompanyInsider OwnershipDAREDare Bioscience4.00%GBIOGeneration Bio21.10%GDTCCytoMed TherapeuticsN/APRPHProPhase Labs9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAREDare Bioscience308.85 million8.50 millionNot OptionableGBIOGeneration Bio15067.04 million52.89 millionOptionableGDTCCytoMed TherapeuticsN/AN/AN/ANot OptionablePRPHProPhase Labs13041.54 million37.55 millionOptionablePRPH, GDTC, DARE, and GBIO HeadlinesRecent News About These CompaniesProPhase Labs Regains Nasdaq Compliance with New AppointmentJuly 1, 2025 | tipranks.comProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule - MorningstarJune 27, 2025 | morningstar.comMProPhase Labs Inc. Receives 180-Day Extension from Nasdaq to Regain Bid Price ComplianceJune 26, 2025 | quiverquant.comQProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price RuleJune 26, 2025 | globenewswire.comProphase Labs Appoints Carolina Abenante as DirectorJune 25, 2025 | tipranks.comProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal CancerJune 17, 2025 | globenewswire.comProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic PlatformJune 6, 2025 | globenewswire.comProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025May 21, 2025 | seekingalpha.comEarnings call transcript: ProPhase Labs beats Q1 2025 EPS forecast, stock risesMay 21, 2025 | investing.comProPhase Labs Inc (PRPH) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ChallengesMay 21, 2025 | finance.yahoo.comProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2025 Earnings Call TranscriptMay 21, 2025 | msn.comProPhase Labs, Inc. (PRPH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | seekingalpha.comProPhase Labs Q1 2025 Earnings PreviewMay 19, 2025 | msn.comProPhase Labs's Earnings OutlookMay 19, 2025 | benzinga.comProPhase Labs Delays Form 10-Q FilingMay 16, 2025 | tipranks.comProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025May 13, 2025 | globenewswire.comCovid Test Lab Weighs Unusual Debt-Collection Plan: BankruptcyMay 13, 2025 | wsj.comProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024April 2, 2025 | seekingalpha.comProPhase Labs reports FY24 EPS ($2.61) vs (98c) last yearApril 1, 2025 | markets.businessinsider.comProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRPH, GDTC, DARE, and GBIO Company DescriptionsDare Bioscience NASDAQ:DARE$2.40 0.00 (0.00%) As of 07/7/2025 04:00 PM EasternDaré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Generation Bio NASDAQ:GBIO$0.33 -0.01 (-3.79%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$0.33 +0.00 (+0.61%) As of 07/7/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.CytoMed Therapeutics NASDAQ:GDTC$2.15 -0.05 (-2.27%) Closing price 07/7/2025 03:12 PM EasternExtended Trading$2.19 +0.04 (+1.81%) As of 07/7/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.ProPhase Labs NASDAQ:PRPH$0.44 +0.02 (+5.64%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$0.44 -0.01 (-1.61%) As of 07/7/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
